DNA疫苗近年备受瞩目,该技术在COVID-19时代得到广泛重视,同时具有潜力用于预防或干预包括阿尔茨海默症在内的神经系统疾病的发展过程。近期Vaccines期刊发表了一篇文献,探讨了DNA疫苗技术在AD免疫和治疗中的主要特点以及所面临的挑战,最终目的是为了有效推动开发安全而有效的AD DNA和RNA疫苗的研究。 doi:10.3390/vaccines1111...
Both protein- and gene-based vaccines (including DNA and RNA) have been explored for COVID-19 and currently on clinical trials. There are several advantages of mRNA vaccines over the other platforms. The first advantage of mRNA vaccines is the easiness and fast speed for their manufacturing. ...
这些发现,加上有效的体内mRNA传递系统的发展,SARS-CoV-2尖峰抗原的稳定化,以及工业和政府的巨大投资,导致了两种非常成功的基于mRNA的COVID-19疫苗在2020年底获得批准。Karikó和Weissman的发现在最需要的时候为使mRNA疫苗平台适用于临床使用起到了关键作用,这为医学做出了非凡的贡献,为未来的mRNA应用铺平了道路。 1987...
第一款sa-mRNA Covid-19疫苗ARCT-154已经由Arcturus Therapeutics和CSL联合开发并于2023年11月29日在日本获得批准。与传统的 mRNA Covid-19 疫苗相比,ARCT-154 的给药剂量是Comirnaty®剂量的六分之一(分别为 5 μg 和 30 μg)。2月初,Arcturus宣布...
There is an urgent need for vaccines against coronavirus disease 2019 (COVID-19) because of the ongoing SARS-CoV-2 pandemic. Among all approaches, a messenger RNA (mRNA)-based vaccine has emerged as a rapid and versatile platform to quickly respond to this challenge. Here, we developed a ...
5，Development and Licensure of Vaccines to Prevent COVID-19https://www.fda.gov/media/139638/...
3. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability; 4. WO2012019780和US20150104476; 5. Protective efficacy of in vitro synthesized,specific messenger RNA vaccines against influenza A virus infection; 6. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity agai...
9. COVID-19 mRNA vaccine candidates and recommended dosage for different ages 10. Transportation of COVID-19 mRNA vaccines and its effect on properties 11. Can the genetic content of COVID-19 mRNA vaccines integrates into the human genome? 12. The impact of mRNA vaccines on the next generat...
截至2021年6月18日,已有185种COVID-19候选疫苗处于临床前开发阶段,另有102种疫苗进入临床试验,其中19种是mRNA疫苗。 2020年12月11日,辉瑞/BioNTech的疫苗BNT162b2获得了FDA紧急授权,成为首个获批的mRNA药物。一周后,Moderna的mRNA-1273也获准在美国使用。辉瑞和BioNTech共同开发了5种编码突刺蛋白抗原变体的mRNA疫苗...
截至2019年底,15种针对传染病的候选mRNA疫苗已进入临床试验,当时,人们认为mRNA疫苗至少还需要5-6年才能获得监管部门的批准。但是,当2020年初COVID-19大流行横行世界时,这些期望就被颠覆了。在接下来的几个月里,mRNA疫苗的研发、制造和部署都进入了飞速跨越的阶段。